Cargando…
Reducing laboratory costs through rational testing in suspected pre-eclampsia
The current electronic laboratory order set at Epsom and St Helier University Hospitals NHS Trust for suspected pre-eclampsia includes a full blood count, urea and electrolytes, liver function, gamma-glutamyltransferase and uric acid. Local and national guidelines do not recommend the use of gamma-g...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915367/ https://www.ncbi.nlm.nih.gov/pubmed/35272997 http://dx.doi.org/10.1136/bmjoq-2021-001684 |
_version_ | 1784668004957552640 |
---|---|
author | Jakes, Adam Daniel Cox, Marsha Drane, Simon Johnson, Antoinette |
author_facet | Jakes, Adam Daniel Cox, Marsha Drane, Simon Johnson, Antoinette |
author_sort | Jakes, Adam Daniel |
collection | PubMed |
description | The current electronic laboratory order set at Epsom and St Helier University Hospitals NHS Trust for suspected pre-eclampsia includes a full blood count, urea and electrolytes, liver function, gamma-glutamyltransferase and uric acid. Local and national guidelines do not recommend the use of gamma-glutamyltransferase or uric acid for the investigation or monitoring of pre-eclampsia, as they are poor predictors of maternal and neonatal outcomes. We aimed to remove the automatic inclusion of gamma-glutamyltransferase and uric acid from the electronic laboratory order set for suspected pre-eclampsia. Stakeholders were approached to gain an understanding of whether gamma-glutamyltransferase and uric acid were being used in the clinical assessment of suspected pre-eclampsia. Obstetric consultants and maternity staff confirmed that they do not use uric acid in their clinical assessment, despite the laboratory phoning with abnormal results. In addition, an isolated gamma-glutamyltransferase rise is of no particular significance and is not part of the National Institute for Health and Care Excellence (NICE) diagnostic criteria for pre-eclampsia. The baseline number of gamma-glutamyltransferase and uric acid requests from the maternity department was identified over 2 months. The hospital information technology service was then asked to remove gamma-glutamyltransferase and uric acid from the electronic laboratory order set. The number of gamma-glutamyltransferase and uric acid requests from the maternity department following the intervention was identified over 2 months. A significant reduction in both gamma-glutamyltransferase and uric acid requests were noted. In addition, the midwives within the maternity assessment unit noted a significant reduction in phone calls from the laboratory to escalate abnormal blood results. This has saved the trust money and reduced staff time answering phone calls regarding abnormal blood results. A repeat assessment at 8 months following the removal of gamma-glutamyltransferase and uric acid demonstrated sustainability of the project. |
format | Online Article Text |
id | pubmed-8915367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-89153672022-03-25 Reducing laboratory costs through rational testing in suspected pre-eclampsia Jakes, Adam Daniel Cox, Marsha Drane, Simon Johnson, Antoinette BMJ Open Qual Quality Improvement Report The current electronic laboratory order set at Epsom and St Helier University Hospitals NHS Trust for suspected pre-eclampsia includes a full blood count, urea and electrolytes, liver function, gamma-glutamyltransferase and uric acid. Local and national guidelines do not recommend the use of gamma-glutamyltransferase or uric acid for the investigation or monitoring of pre-eclampsia, as they are poor predictors of maternal and neonatal outcomes. We aimed to remove the automatic inclusion of gamma-glutamyltransferase and uric acid from the electronic laboratory order set for suspected pre-eclampsia. Stakeholders were approached to gain an understanding of whether gamma-glutamyltransferase and uric acid were being used in the clinical assessment of suspected pre-eclampsia. Obstetric consultants and maternity staff confirmed that they do not use uric acid in their clinical assessment, despite the laboratory phoning with abnormal results. In addition, an isolated gamma-glutamyltransferase rise is of no particular significance and is not part of the National Institute for Health and Care Excellence (NICE) diagnostic criteria for pre-eclampsia. The baseline number of gamma-glutamyltransferase and uric acid requests from the maternity department was identified over 2 months. The hospital information technology service was then asked to remove gamma-glutamyltransferase and uric acid from the electronic laboratory order set. The number of gamma-glutamyltransferase and uric acid requests from the maternity department following the intervention was identified over 2 months. A significant reduction in both gamma-glutamyltransferase and uric acid requests were noted. In addition, the midwives within the maternity assessment unit noted a significant reduction in phone calls from the laboratory to escalate abnormal blood results. This has saved the trust money and reduced staff time answering phone calls regarding abnormal blood results. A repeat assessment at 8 months following the removal of gamma-glutamyltransferase and uric acid demonstrated sustainability of the project. BMJ Publishing Group 2022-03-10 /pmc/articles/PMC8915367/ /pubmed/35272997 http://dx.doi.org/10.1136/bmjoq-2021-001684 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Quality Improvement Report Jakes, Adam Daniel Cox, Marsha Drane, Simon Johnson, Antoinette Reducing laboratory costs through rational testing in suspected pre-eclampsia |
title | Reducing laboratory costs through rational testing in suspected pre-eclampsia |
title_full | Reducing laboratory costs through rational testing in suspected pre-eclampsia |
title_fullStr | Reducing laboratory costs through rational testing in suspected pre-eclampsia |
title_full_unstemmed | Reducing laboratory costs through rational testing in suspected pre-eclampsia |
title_short | Reducing laboratory costs through rational testing in suspected pre-eclampsia |
title_sort | reducing laboratory costs through rational testing in suspected pre-eclampsia |
topic | Quality Improvement Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915367/ https://www.ncbi.nlm.nih.gov/pubmed/35272997 http://dx.doi.org/10.1136/bmjoq-2021-001684 |
work_keys_str_mv | AT jakesadamdaniel reducinglaboratorycoststhroughrationaltestinginsuspectedpreeclampsia AT coxmarsha reducinglaboratorycoststhroughrationaltestinginsuspectedpreeclampsia AT dranesimon reducinglaboratorycoststhroughrationaltestinginsuspectedpreeclampsia AT johnsonantoinette reducinglaboratorycoststhroughrationaltestinginsuspectedpreeclampsia |